SJEPD030627_D1.RNA-Seq
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 13.71
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -2.542449646
- umap2_2d
- 2.456476928
- umap1_3d
- -0.230857601
- umap2_3d
- 3.165801481
- umap3_3d
- -2.550678393
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.510
- INFLAMMATORY_RESPONSE+0.480
- INTERFERON_GAMMA_RESPONSE+0.470
- IL6_JAK_STAT3_SIGNALING+0.460
- INTERFERON_ALPHA_RESPONSE+0.410
- IL2_STAT5_SIGNALING+0.400
- MITOTIC_SPINDLE+0.390
- COMPLEMENT+0.380
- E2F_TARGETS+0.380
- G2M_CHECKPOINT+0.380
Top 10 suppressed
- BILE_ACID_METABOLISM-0.310
- PEROXISOME-0.220
- CHOLESTEROL_HOMEOSTASIS-0.190
- PANCREAS_BETA_CELLS-0.190
- OXIDATIVE_PHOSPHORYLATION-0.160
- SPERMATOGENESIS-0.140
- KRAS_SIGNALING_DN-0.070
- XENOBIOTIC_METABOLISM-0.060
- FATTY_ACID_METABOLISM-0.050
- HYPOXIA-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088815 | — | — | 0.895 |
| 2 | TCGA-52-7622-01A-11R-2125-07 | — | cohortSQ1 | 0.879 |
| 3 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.876 |
| 4 | TCGA-56-8201-01A-11R-2247-07 | — | cohortA1 | 0.875 |
| 5 | TCGA-XF-A9SY-01A-21R-A42T-07 | — | — | 0.872 |
| 6 | TCGA-CR-7373-01A-11R-2016-07 | — | — | 0.860 |
| 7 | TCGA-FD-A3B7-01A-31R-A20F-07 | — | — | 0.856 |
| 8 | TCGA-LC-A66R-01A-41R-A30C-07 | — | — | 0.855 |
| 9 | SRR934956 | — | — | 0.855 |
| 10 | R409 | — | — | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |